Dear Fellow Investor,
Health Care’s Quiet Rotation Is Broadening: 3 Stocks Positioned to Benefit
Health care is quietly stepping back into the spotlight, and the most interesting part is that it is not behaving like a purely defensive trade.
Yes, health care has historically served as a steadier corner of the market during periods of uncertainty. But the recent shift has a different feel: the sector has flashed a rare historical signal, one that has not appeared often over the last few decades. When this type of setup has emerged in prior cycles, health care has often gone on to deliver meaningful relative outperformance.
The second notable detail is how the move has developed. For much of the year, gains were concentrated in a relatively small cluster of high-quality leaders, exactly the kind of narrow participation that can make a sector rally look stronger than it really is. Narrow leadership can persist, but it is also vulnerable: if the leaders stall, the entire theme can fade quickly.
That is why the current phase matters. What began as a “stealth rotation” is now broadening. More companies are joining the uptrend, and investor attention is expanding from a handful of familiar winners to a deeper bench across the industry. In market terms, improving breadth is often what turns a short-lived move into a more durable trend because it suggests the bid is not reliant on one or two names carrying the whole group.
For long-term investors, this kind of broadening can be a meaningful tell. When participation improves, it can indicate that the market is starting to price in better fundamentals across the sector: stabilizing demand, a more constructive earnings outlook, improving visibility, or even a shift in how investors value cash flows. And in health care specifically, broadening participation can also reflect a rotation toward businesses with recurring demand drivers that are less sensitive to the economic cycle.
With that backdrop, here is a look at three health care stocks that appear well positioned to benefit from a stronger, broader sector tape - supported by buy ratings from major firms and constructive implied upside to price targets.
Company: Agilent Technologies (SYM: A)
Picks-and-shovels exposure to life sciences and diagnostics
Recent Price: $141.74
Price Target: $168.08
Firms with Buy Rating: Morgan Stanley, Goldman Sachs, UBS
Agilent operates as an applications-focused provider to the life sciences, diagnostics, and applied chemical markets. Its business spans three segments, Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, giving it broad exposure to the tools and services that support research, testing, and clinical workflows.
From an investor perspective, Agilent is often viewed as a “picks-and-shovels” way to participate in long-run health care and biotech innovation. Instead of betting on the success of a single drug, it sells essential instruments, consumables, and services that are used across many customers and end markets. In many cycles, that positioning can translate into a more resilient demand profile, especially when the company has a meaningful installed base and recurring service or consumables revenue.
Why might it benefit as the rotation broadens? When breadth improves in health care, it is often because investors are looking beyond headline drug makers and into the ecosystem that supports the entire innovation pipeline. As confidence improves around research activity, diagnostics demand, or clinical testing volumes, the market frequently re-rates the enabling platforms that sit behind the scenes.
Analyst support from multiple major firms suggests confidence in the company’s ability to execute through the next phase. The implied upside to target also indicates that, even after recent strength in parts of health care, some on the Street still see valuation room if fundamentals and sentiment continue to firm.
What to watch into 2026: order trends, lab spending cycles, and whether the mix continues to favor higher-value workflow solutions, factors that can influence both growth and margin structure.
Trading Whisperer
Wall Street’s New ETF Targets Global Money Movement
Money movement is changing faster than anyone expected.
Data centers run 24 hours. E-commerce runs 24 hours. Now finance is racing to catch up.
A newly listed ETF just opened the door to that evolution, offering a direct play on instant settlement through a simple, US listed wrapper.
Second-level finality. Institutional custody.
You trade it like any other fund. It reports like any other fund.
And while others chase hype, this product is built for discipline. Single asset exposure, no leverage, no hidden overlays, and a clear 0.50% sponsor fee.*
Every previous digital-asset ETF proved the appetite. Strong volume. Rapid AUM. A growing share of portfolios that used to avoid the space entirely.
This one brings that same structure to the payments side, the part of finance where efficiency actually pays.
The window to get in early is open. Learn more now.
Get the symbol before the crowd.
Company: AbbVie (SYM: ABBV)
A scale biopharma story with multiple franchises
Recent Price: $223.58
Price Target: $248.67
Firms with Buy Rating: HSBC, Piper Sandler, J.P. Morgan
AbbVie is a research-based biopharmaceutical company with a broad global portfolio spanning immunology, oncology, neuroscience, eye care, virology, and more. Investors most commonly associate AbbVie with major immunology therapies, historically Humira and, increasingly, newer therapies such as Skyrizi and Rinvoq, alongside a wide set of other branded medicines and aesthetics products.
In a broadening health care tape, AbbVie can stand out for a different reason than tools companies: it combines scale, cash flow, and diversified end markets. When investors re-engage with health care beyond the “defensive” framing, large, profitable biopharma companies with multiple growth drivers and strong commercial execution often re-enter the conversation as core holdings, not just tactical positions.
The appeal is typically a blend of durability and optionality:
-
Durability because demand for many therapies is not tightly linked to GDP growth.
-
Optionality because successful drug franchises, label expansions, and pipeline progress can create upside that is not always reflected in near-term numbers.
Analyst buy ratings across multiple firms suggest a constructive outlook on AbbVie’s ability to sustain performance as its portfolio evolves. The gap between the recent price and target is not extreme, but it still implies further upside if execution and earnings visibility remain strong.
What to watch into 2026: continued performance across key franchises, competitive dynamics in major therapeutic areas, and any pipeline catalysts that could expand the company’s growth profile.
Crypto 101
Get in before the new year rally hits
Let me tell you something about memecoins...when they move, they move FAST.
We're not talking about slow, steady 20% gains over months. We're talking about:
→ 600% in a single day
→ 1,100% in 48 hours
→ 8,200% in 5 months
That's the kind of speed we've seen from my analysts Brian and Joe, who have developed a system for identifying memecoins before they explode.
The market is oversold. Fear is everywhere. Most investors are sitting on the sidelines waiting for "confirmation."
But January has historically been one of crypto's strongest months. A new year rally could be building as we speak. And when momentum returns to the market, memecoins don't just participate…they lead.
Brian and Joe just flagged their #1 memecoin for January 2026. It's still trading for pennies. It has viral energy, real utility, and a capped supply with a burn mechanism built in.
You can get the full report—what the coin is, how to buy it, and exactly what to expect—right now:
Get the #1 Memecoin for January 2026 here
Company: Thermo Fisher Scientific (SYM: TMO)
A category leader across the life science stack
Recent Price: $567.36
Price Target: $631.80
Firms with Buy Rating: Goldman Sachs, Morgan Stanley, Barclays
Thermo Fisher is one of the most strategically important companies in the life sciences ecosystem. It provides solutions across analytical instruments, specialty diagnostics, lab products, and biopharma services, selling everything from research consumables to sophisticated instrumentation and services supporting drug development and manufacturing.
Thermo Fisher’s breadth matters. In a sector rotation that is broadening, businesses with multiple demand drivers can be especially attractive because they are not dependent on one narrow pocket of the industry. The company’s segments span research and discovery, clinical and diagnostic testing, and bioproduction services, areas that can take turns leading depending on the cycle.
Analysts who like Thermo Fisher often point to a few structural strengths:
-
Scale and customer reach: It is embedded across pharma, biotech, academia, government, and industrial markets.
-
Recurring demand: Many product categories are consumables- or service-heavy, supporting repeat purchases.
-
Strategic positioning in biopharma services: Outsourcing trends and the complexity of biologics manufacturing can support long-run demand for specialized capabilities.
The implied upside to the target suggests analysts see room for appreciation if the market continues to reward health care “infrastructure” businesses as the rotation widens.
What to watch into 2026: biopharma funding and production trends, research activity levels, and how management balances growth and margin priorities across segments.
Paradigm Press
This Backdoor Play on Starlink’s IPO for Less than $100?
Whenever Elon Musk goes “all in” on something, it always generates HUGE excitement and opportunity. His latest project, Starlink – with its mission to provide satellite Internet to every corner of the globe – is no exception. And one man says it will soon go public, at an estimated $100 BILLION valuation. That would make it the biggest IPO in HISTORY… Roughly 228X BIGGER than Amazon’s IPO. Today, investing legend James Altucher has uncovered a smart, unconventional way to potentially benefit from the impending Starlink IPO… This backdoor play lets savvy investors like you engage with Starlink’s promise without the need for direct initial IPO access.Click here to learn how.
What other stocks do you have your eye on heading into 2026? What other sectors of the market are you currently interested in? Hit "reply" to this email and let us know your thoughts!
